Virus News and Research

Latest Virus News and Research

Australian epidemics research programme to be disbanded

The Australian Federal Government scrapped the funding to the Australian National University’s Master of Applied Epidemiology (MAE) program. This group helps Australia’s response to major disease outbreak and will be disbanded at the end of next year. According to Emeritus Professor Robert Douglas who founded this program, this has been responsible for Australia’s response to serious epidemic outbreaks in the past.

14 Nov 2010

Neurologix third quarter net loss decreases to $2.3 million

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system ("CNS"), today reported its financial results for the three and nine months ended September 30, 2010.

12 Nov 2010

Targeted Genetics enters definitive agreements to acquire Biocontrol

Targeted Genetics Corporation, today announced that it has entered into definitive agreements related to the acquisition of Biocontrol Limited, or Biocontrol.

12 Nov 2010

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

The 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) brings together leading allergists and immunologists from around the world.

12 Nov 2010

Stanford University scientist receives HFSP Nakasone Award for neuronal network study

The first HFSP Nakasone Award has been conferred upon Karl Deisseroth of Stanford University for his pioneering work on the development of optogenetic methods for studying the function of neuronal networks underlying behavior.

12 Nov 2010

SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors

Drug discovery and development company SCYNEXIS, Inc. today announced that the Company has been awarded four grants totaling $977,917 under the U.S. Federal Government's Qualifying Therapeutic Discovery Project (QTDP). SCYNEXIS is developing a proprietary internal pipeline of cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases.

11 Nov 2010

Pevion announces positive results of PEV7 Phase I study for recurrent vulvovaginal candidiasis

Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC).

11 Nov 2010

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.

11 Nov 2010

New study sheds light on Immune Reconstitution Inflammatory Syndrome

Newly published research by scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, sheds light on a poorly understood, acute illness called Immune Reconstitution Inflammatory Syndrome (IRIS) that develops in some HIV-infected individuals soon after they begin antiretroviral therapy.

11 Nov 2010

Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C

Children with hepatitis C fare decidedly better with a supercharged combination of two antiviral drugs than with the usual and standard single-drug regimen, according to research led by investigators at the Johns Hopkins Children Center.

11 Nov 2010

Researchers find text messages to HIV patients improve adherence, health outcomes in Kenya trial

Using mobile-phone text messages to remind HIV patients to take their dose of life-saving medications can give a major boost to drug adherence, according to an innovative trial in Kenya unveiled on Tuesday, Agence France-Presse reports.

10 Nov 2010

Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV

Vertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.

10 Nov 2010

HPV vaccination rates falter

According to the latest research lesser numbers of teenage girls and young women are getting infected by the human papillomavirus vaccine (HPV) – a virus linked to cervical cancer. Research also shows that most who start the vaccination regimen against the virus fail to take all three doses.

10 Nov 2010

Contraceptive, antiviral gel using bee venom wins 2010 Gates Foundation grant

A vaginal gel that affords both contraception and HIV protection using nanoparticles that carry bee venom is one of the bold, unconventional ideas that won a 2010 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation.

10 Nov 2010

World Lung Foundation report highlights prevalence of acute respiratory infections worldwide

Acute respiratory infections (ARIs) - such as influenza, pneumonia and respiratory syncytial virus (RSV) - cause 4.25 million deaths each year often among young children in developing countries, according to the Acute Respiratory Infections Atlas, which was released on Tuesday by the World Lung Foundation, Reuters reports (11/9).

10 Nov 2010

New York Times examines HIV prevention products undergoing clinical trials

The New York Times examines several products being studied in clinical trials that researchers hope will one day prevent sexual transmission of HIV. The newspaper describes the ongoing trials of a vaginal microbicide gel containing the antiretroviral tenofovir which was found to reduce the risk of HIV infection in women by 39 percent, writing, "[o]ther clinical trials will report their results in 2011 and 2012 and, if all goes well, researchers hope to have a product or two ready to enter the market by 2013."

10 Nov 2010

Patented cover for stethoscopes will curb hospital-acquired infections

Saints Medical Center is pleased to announce that Richard H. Ma, M.D, chair of its hospitalist department, has received a patent for a lightweight plastic cover for stethoscopes that will dramatically reduce hospital-acquired infections.

9 Nov 2010

Innovative method for in-cell gene manipulation

A cross-disciplinary Small Medicine and Advanced Research Translation (SMART) team led by Prof. Dar-Bin Shieh of Institute of Oral Medicine in Medical College at National Cheng Kung University (NCKU), Tainan, Taiwan, has announced a breakthrough in the precision in-cell gene scission at pre-designed sequence sites using Artificial Targeting Light Activated Nano Scissors (ATLANS) and a custom build photonic device.

9 Nov 2010

Researchers examine burden of HIV and sexually transmitted diseases in China

A new study by researchers at the Johns Hopkins Bloomberg School of Public Health examines the burden of HIV and sexually transmitted disease among male clients of the commercial sex industry in China's Sichuan province

9 Nov 2010

ORVACS launches ERAMUNE 01 Phase II study to decrease HIV viral reservoirs

ORVACS has launched a Phase II study designed to test the hypotheses that combination therapy with potent antiviral agents and immunomodulator can lead to a decrease in the HIV viral reservoirs and, ultimately, to eradication of the virus. The study is currently being conducted at clinical sites in France, Spain, Italy, and the United Kingdom.

9 Nov 2010

Virus News and Research

Latest Virus News and Research

Australian epidemics research programme to be disbanded

Neurologix third quarter net loss decreases to $2.3 million

Targeted Genetics enters definitive agreements to acquire Biocontrol

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

Stanford University scientist receives HFSP Nakasone Award for neuronal network study

SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors

Pevion announces positive results of PEV7 Phase I study for recurrent vulvovaginal candidiasis

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

New study sheds light on Immune Reconstitution Inflammatory Syndrome

Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C

Researchers find text messages to HIV patients improve adherence, health outcomes in Kenya trial

Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV

HPV vaccination rates falter

Contraceptive, antiviral gel using bee venom wins 2010 Gates Foundation grant

World Lung Foundation report highlights prevalence of acute respiratory infections worldwide

New York Times examines HIV prevention products undergoing clinical trials

Patented cover for stethoscopes will curb hospital-acquired infections

Innovative method for in-cell gene manipulation

Researchers examine burden of HIV and sexually transmitted diseases in China

ORVACS launches ERAMUNE 01 Phase II study to decrease HIV viral reservoirs

A new way of characterising biomolecules eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in